JP5209463B2 - アシル化ｇｌｐ−１化合物 - Google Patents

アシル化ｇｌｐ−１化合物 Download PDF

Info

Publication number: JP5209463B2
Authority: JP; Japan
Prior art keywords: ethoxy; glp; peptide; acetyl; arg34
Prior art date: 2005-03-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2008501334A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008533105A (ja

JP2008533105A5 (2

Inventor

ラウ、イェスパー

デールワルド、フロレンシオ・ザラゴザ

ステッペンセン、ヘンリク

ブロホ、パウ

ハンセン、トマス・クルーセ

マドセン、キエルド

Original Assignee

ノヴォノルディスクアー／エス

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-18

Filing date

2006-03-20

Publication date

2013-06-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36821525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5209463(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-03-20 Application filed by ノヴォノルディスクアー／エス filed Critical ノヴォノルディスクアー／エス

2008-08-21 Publication of JP2008533105A publication Critical patent/JP2008533105A/ja

2008-11-06 Publication of JP2008533105A5 publication Critical patent/JP2008533105A5/ja

2013-06-12 Application granted granted Critical

2013-06-12 Publication of JP5209463B2 publication Critical patent/JP5209463B2/ja

2026-03-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

0 C*(C*C(NO)=O)C(C)=O Chemical compound C*(C*C(NO)=O)C(C)=O 0.000 description 6

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)

JP2008501334A 2005-03-18 2006-03-20 アシル化ｇｌｐ−１化合物 Expired - Lifetime JP5209463B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05102171.5		2005-03-18
EP05102171		2005-03-18
PCT/EP2006/060855 WO2006097537A2 (en)	2005-03-18	2006-03-20	Acylated glp-1 compounds

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2010009025A Division JP4585037B2 (ja)	2005-03-18	2010-01-19	アシル化ｇｌｐ−１化合物
JP2012242654A Division JP2013063984A (ja)	2005-03-18	2012-11-02	アシル化ｇｌｐ−１化合物

Publications (3)

Publication Number	Publication Date
JP2008533105A JP2008533105A (ja)	2008-08-21
JP2008533105A5 JP2008533105A5 (2)	2008-11-06
JP5209463B2 true JP5209463B2 (ja)	2013-06-12

Family

ID=36821525

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2008501334A Expired - Lifetime JP5209463B2 (ja)	2005-03-18	2006-03-20	アシル化ｇｌｐ−１化合物
JP2010009025A Expired - Lifetime JP4585037B2 (ja)	2005-03-18	2010-01-19	アシル化ｇｌｐ−１化合物
JP2012242654A Withdrawn JP2013063984A (ja)	2005-03-18	2012-11-02	アシル化ｇｌｐ−１化合物

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2010009025A Expired - Lifetime JP4585037B2 (ja)	2005-03-18	2010-01-19	アシル化ｇｌｐ−１化合物
JP2012242654A Withdrawn JP2013063984A (ja)	2005-03-18	2012-11-02	アシル化ｇｌｐ−１化合物

Country Status (25)

Country	Link
US (2)	US8129343B2 (2)
EP (2)	EP1863839B1 (2)
JP (3)	JP5209463B2 (2)
KR (1)	KR101205272B1 (2)
CN (3)	CN104402989A (2)
AT (1)	ATE476446T1 (2)
AU (1)	AU2006224536B9 (2)
BE (1)	BE2018C016I2 (2)
BR (2)	BR122019002626A2 (2)
CA (1)	CA2601784C (2)
DE (1)	DE602006015928D1 (2)
DK (2)	DK2322546T3 (2)
ES (2)	ES2350051T3 (2)
FR (1)	FR18C1017I2 (2)
HU (2)	HUE028194T2 (2)
IL (1)	IL184051A (2)
MX (1)	MX2007011220A (2)
NL (1)	NL300936I2 (2)
NO (2)	NO337946B1 (2)
PL (2)	PL1863839T3 (2)
PT (2)	PT2322546E (2)
RU (1)	RU2434019C3 (2)
TW (2)	TWI372629B (2)
WO (1)	WO2006097537A2 (2)
ZA (1)	ZA200707261B (2)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658938B2 (en)	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
KR101241862B1 (ko) *	2003-09-19	2013-03-13	노보 노르디스크 에이/에스	신규 ｇｌｐ-1 유도체
US20060046962A1 (en)	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Absorption enhancers for drug administration
US8268791B2 (en) *	2004-08-25	2012-09-18	Aegis Therapeutics, Llc.	Alkylglycoside compositions for drug administration
US20140162965A1 (en)	2004-08-25	2014-06-12	Aegis Therapeutics, Inc.	Compositions for oral drug administration
US9895444B2 (en)	2004-08-25	2018-02-20	Aegis Therapeutics, Llc	Compositions for drug administration
US8030273B2 (en)	2004-10-07	2011-10-04	Novo Nordisk A/S	Protracted exendin-4 compounds
US7893017B2 (en)	2004-10-07	2011-02-22	Novo Nordisk A/S	Protracted GLP-1 compounds
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
JP5755398B2 (ja)	2005-03-18	2015-07-29	ノヴォノルディスクアー／エス	伸長されたｇｌｐ−１化合物
TWI372629B (en) *	2005-03-18	2012-09-21	Novo Nordisk As	Acylated glp-1 compounds
CN100374462C (zh) *	2005-11-21	2008-03-12	大连帝恩生物工程有限公司	截短胰高血糖素样肽1(sGLP-1)、制法及其应用
KR101191322B1 (ko)	2006-04-07	2012-10-16	메리온 리서치 Ⅲ 리미티드	증진제를 함유하는 고형 경구용 투여 제형
US20090326193A1 (en) *	2006-06-23	2009-12-31	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) *	2006-06-23	2011-08-16	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) *	2006-06-23	2012-05-08	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) *	2006-06-23	2012-07-24	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) *	2006-06-23	2008-09-16	Aegis Therapeutics, Inc.	Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) *	2006-06-23	2011-12-27	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US20100261637A1 (en) *	2007-09-05	2010-10-14	Novo Nordisk A/S	Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en)	2007-09-05	2018-03-14	Novo Nordisk A/S	Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030774A1 (en) *	2007-09-05	2009-03-12	Novo Nordisk A/S	Truncated glp-1 derivatives and their therapeutical use
JP5241849B2 (ja)	2007-11-16	2013-07-17	ノボ・ノルデイスク・エー／エス	インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
US20100317057A1 (en) *	2007-12-28	2010-12-16	Novo Nordisk A/S	Semi-recombinant preparation of glp-1 analogues
CN102037008B (zh)	2008-03-18	2016-08-31	诺沃-诺迪斯克有限公司	蛋白酶稳定化的、酰化胰岛素类似物
CA2756690C (en)	2008-03-28	2016-08-16	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
CN107096012A (zh)	2008-05-07	2017-08-29	诺和诺德股份有限公司	肽的组合物及其制备方法
KR20110039348A (ko) *	2008-08-06	2011-04-15	노보 노르디스크 헬스 케어 악티엔게젤샤프트	연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US8637647B2 (en)	2008-09-12	2014-01-28	Novo Nordisk A/S	Method of acylating a peptide or protein
US8440631B2 (en)	2008-12-22	2013-05-14	Aegis Therapeutics, Llc	Compositions for drug administration
JP5816097B2 (ja)	2009-01-22	2015-11-18	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
BRPI1007313A2 (pt)	2009-01-23	2016-02-10	Novo Nordisk As	derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
EP2440235A1 (en) *	2009-06-11	2012-04-18	Novo Nordisk A/S	Glp-1 and fgf21 combinations for treatment of diabetes type 2
AP3329A (en)	2009-07-13	2015-06-30	Zealand Pharma As	Acylated glucagon analogues
JP6086528B2 (ja)	2009-08-06	2017-03-01	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	長期のインビボ有効性を有する成長ホルモン
EP2512518A1 (en)	2009-12-16	2012-10-24	Novo Nordisk A/S	Glp-1 receptor agonist compounds with a modified n-terminus
JP5980689B2 (ja)	2010-01-22	2016-08-31	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
CN118767117A (zh)	2010-01-22	2024-10-15	诺沃—诺迪斯克保健股份有限公司	体内功效延长的生长激素
EP2539364A1 (en)	2010-02-26	2013-01-02	Novo Nordisk A/S	Peptides for treatment of obesity
WO2011120033A1 (en)	2010-03-26	2011-09-29	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor xa inhibitors for oral administration
EP2552950A1 (en)	2010-03-26	2013-02-06	Novo Nordisk A/S	Novel glucagon analogues
BR112012027545B1 (pt) *	2010-04-27	2020-09-24	Betta Pharmaceuticals Co., Ltd.	Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
CN102186881B (zh) *	2010-04-27	2015-04-08	贝达药业股份有限公司	胰高血糖素样肽-1衍生物及其应用
WO2011143788A1 (en) *	2010-05-17	2011-11-24	Zhejiang Beta Pharma Inc.	Novel glucagon like peptide analogs, composition, and method of use
WO2012016419A1 (zh) *	2010-08-06	2012-02-09	浙江贝达药业有限公司	Glp-1衍生物及其应用
EP2637698B1 (en)	2010-11-09	2022-04-20	Novo Nordisk A/S	Double-acylated glp-1 derivatives
MX377589B (es) *	2010-12-16	2025-03-10	Novo Nordisk As	Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
EP2661273A4 (en)	2011-01-07	2014-06-04	Merrion Res Iii Ltd	IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
US20140045754A1 (en)	2011-01-19	2014-02-13	Joern Drustrup	Glp-1 compositions
US20140004198A1 (en)	2011-01-19	2014-01-02	Novo Nordisk A/S	Glp-1 particles and compositions
JP2014510739A (ja) *	2011-03-28	2014-05-01	ノヴォノルディスクアー／エス	新規のグルカゴン類似体
KR101496136B1 (ko) *	2011-03-30	2015-02-26	베타 파머수티컬 컴퍼니 리미티드	글루카곤 유사 펩타이드-1 유사체 및 이의 용도
ES2712945T3 (es) *	2011-04-12	2019-05-16	Novo Nordisk As	Derivados de GLP-1 doblemente acilados
RU2602601C2 (ru) *	2011-04-12	2016-11-20	Ново Нордиск А/С	Дважды ацилированные производные glp-1
EP4085899A1 (en)	2011-06-14	2022-11-09	Neurelis, Inc.	Administration of benzodiazepine
KR20140053991A (ko)	2011-07-18	2014-05-08	아츠 바이올로직스 에이/에스	장기간 작용하는 황체 형성 호르몬 (ｌｈ) 화합물
EP2753642B8 (en)	2011-09-06	2017-12-13	Novo Nordisk A/S	Glp-1 derivatives
RU2610175C2 (ru)	2011-09-23	2017-02-08	Ново Нордиск А/С	Новые аналоги глюкагона
JP6046161B2 (ja)	2011-12-29	2016-12-14	ノヴォノルディスクアー／エス	非タンパク質新生アミノ酸を含むジペプチド
JP6400480B2 (ja)	2012-02-15	2018-10-03	ノヴォノルディスクアー／エス	ペプチドグリカン認識タンパク質１に結合する抗体
SMT201700488T1 (it)	2012-02-15	2017-11-15	Novo Nordisk As	Anticorpi che legano e bloccano il recettore d'innesco espresso sulle cellule mieloidi-1 (trem-1)
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP3542790B1 (en)	2012-03-22	2023-09-13	Novo Nordisk A/S	Compositions comprising a delivery agent and preparation thereof
CN104203266B (zh)	2012-03-22	2017-12-26	诺和诺德股份有限公司	Glp‑1肽组合物及其制备
PT2827885T (pt) *	2012-03-22	2018-11-05	Novo Nordisk As	Composições de péptidos glp-1 e sua preparação
DK2827845T3 (en)	2012-03-22	2019-04-01	Novo Nordisk As	COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
JP6228187B2 (ja)	2012-05-03	2017-11-08	ジーランドファーマアクティーゼルスカブ	Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP6250034B2 (ja)	2012-05-08	2017-12-20	ノヴォノルディスクアー／エス	二重アシル化されたｇｌｐ−１誘導体
ES2629735T3 (es) *	2012-05-08	2017-08-14	Novo Nordisk A/S	Derivados de GLP-1 doblemente acilados
WO2013170636A1 (zh)	2012-05-18	2013-11-21	爱德迪安（北京）生物技术有限公司	用于糖尿病治疗的蛋白、蛋白缀合物及其应用
JP6517690B2 (ja) *	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
HRP20251088T1 (hr)	2012-07-01	2025-11-07	Novo Nordisk A/S	Upotreba dugodjelujućih peptida glp‑1
AU2013295035B2 (en)	2012-07-23	2017-08-03	Zealand Pharma A/S	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US20150273069A1 (en) *	2012-10-17	2015-10-01	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
SI2986313T1 (sl)	2013-04-18	2019-09-30	Novo Nordisk A/S	Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
JP6672140B2 (ja)	2013-05-02	2020-03-25	ノヴォノルディスクアー／エス	Ｇｌｐ−１化合物の経口投薬
KR20160021183A (ko) *	2013-06-20	2016-02-24	노보 노르디스크 에이/에스	Glp-1 유도체 및 그것의 용도
WO2015000942A1 (en)	2013-07-04	2015-01-08	Novo Nordisk A/S	Derivatives of glp-1 like peptides, and uses thereof
US10266577B2 (en)	2013-08-15	2019-04-23	Novo Nordisk A/S	GLP-1 derivatives, and uses thereof
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
CN105792851B (zh)	2013-09-13	2023-10-10	斯克利普斯研究所	修饰的治疗剂及其组合物
WO2015055801A1 (en)	2013-10-17	2015-04-23	Zealand Pharma A/S	Acylated glucagon analogues
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
AU2014345570B2 (en)	2013-11-06	2019-01-24	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
MX2016005556A (es) *	2013-11-06	2016-07-15	Zealand Pharma As	Compuestos agonistas duales de gip-glp-1 y procedimientos.
CN112043835B (zh)	2013-12-06	2022-10-21	韩捷	用于含氮和羟基的药物的生物可逆引入基团
AU2014364589B2 (en) *	2013-12-18	2020-02-27	The California Institute For Biomedical Research	Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2015124612A1 (en)	2014-02-18	2015-08-27	Novo Nordisk A/S	Stable glucagon analogues and use for treatment of hypoglycaemia
US10689429B2 (en)	2014-04-07	2020-06-23	Novo Nordisk A/S	Double-acylated GLP-1 compounds
SI3139948T1 (sl)	2014-05-07	2020-07-31	Novo Nordisk A/S	Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
EP3172232B1 (en)	2014-07-17	2023-12-27	Novo Nordisk A/S	Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
US10968266B2 (en)	2014-09-05	2021-04-06	University Of Copenhagen	GIP peptide analogues
GR20140100479A (el) *	2014-09-23	2016-05-05	Novetide, Ltd.,	Συνθεση λιραγλουτιδης
DK3006045T3 (en)	2014-10-07	2017-07-17	Cyprumed Gmbh	Pharmaceutical formulations for oral administration of peptide or protein drugs
US10253078B2 (en)	2014-10-29	2019-04-09	Zealand Pharma A/S	GIP agonist compounds and methods
JP6730278B2 (ja) *	2014-11-27	2020-07-29	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en)	2014-12-17	2016-06-23	Novo Nordisk A/S	Glp-1 derivatives and uses thereof
AR103246A1 (es)	2014-12-23	2017-04-26	Novo Nordiks As	Derivados de fgf21 y sus usos
CN107205949A (zh) *	2015-01-29	2017-09-26	诺和诺德股份有限公司	包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
US10265384B2 (en)	2015-01-29	2019-04-23	Novo Nordisk A/S	Tablets comprising GLP-1 agonist and enteric coating
US10336802B2 (en)	2015-04-16	2019-07-02	Zealand Pharma A/S	Acylated glucagon analogue
CN107708667A (zh) *	2015-06-16	2018-02-16	太阳医药高级研发有限公司	长效利拉鲁肽组合物
WO2016205488A1 (en)	2015-06-17	2016-12-22	The California Institute For Biomedical Research	Modified therapeutic agents and compositions thereof
CN106554403B (zh) *	2015-09-25	2021-08-31	博瑞生物医药（苏州）股份有限公司	艾塞那肽修饰物及其用途
CN106554409B (zh) *	2015-09-30	2020-04-07	天津药物研究院有限公司	一种长效胰高血糖素样肽-1类似物及其应用
CN106554408A (zh) *	2015-09-30	2017-04-05	天津药物研究院有限公司	长效胰高血糖素样肽-1类似物二聚体及其应用
EP3359181A1 (en)	2015-10-07	2018-08-15	Cyprumed GmbH	Pharmaceutical formulations for the oral delivery of peptide drugs
CN106928343A (zh) *	2015-12-30	2017-07-07	深圳翰宇药业股份有限公司	索玛鲁肽的制备方法
WO2017149070A1 (en)	2016-03-03	2017-09-08	Novo Nordisk A/S	Glp-1 derivatives and uses thereof
CN107266557B (zh) *	2016-04-06	2020-04-07	天津药物研究院有限公司	一种聚乙二醇修饰的胰高血糖素样肽-1类似物
JP7221694B2 (ja)	2016-04-28	2023-02-14	ノヴォノルディスクアー／エス	心血管状態におけるセマグルチド
WO2018065634A1 (en)	2016-10-07	2018-04-12	Cyprumed Gmbh	Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
WO2018078112A1 (en)	2016-10-27	2018-05-03	Aarhus Universitet	Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
MA46780A (fr)	2016-11-07	2019-09-11	Novo Nordisk As	Esters à dchbs actif de composés peg et leur utilisation
TWI700091B (zh)	2016-12-16	2020-08-01	丹麥商諾佛儂迪克股份有限公司	含胰島素醫藥組成物
CN107033234B (zh) *	2017-01-03	2018-06-26	北京凯因科技股份有限公司	酰化的glp-1衍生物
CN110545838A (zh) *	2017-03-08	2019-12-06	因塔西亚制药公司	用于从药物递送装置施用致恶心化合物的设备和方法
PL3630806T3 (pl)	2017-05-31	2024-05-13	The University Of Copenhagen	Analogi peptydów gip o długotrwałym działaniu
AR112015A1 (es)	2017-06-09	2019-09-11	Novo Nordisk As	Composiciones sólidas para administración oral
CN109248323B (zh) *	2017-07-14	2023-09-08	杭州先为达生物科技有限公司	酰化的glp-1衍生物
EP3655427A1 (en) *	2017-07-19	2020-05-27	Novo Nordisk A/S	Bifunctional compounds
HRP20240485T1 (hr) *	2017-08-24	2024-07-05	Novo Nordisk A/S	Pripravci glp-1 i njihova upotreba
CN111163795A (zh)	2017-09-10	2020-05-15	诺沃挪第克公司	用于治疗肥胖症的mic-1和glp-1
US11357861B2 (en)	2017-09-29	2022-06-14	Hanmi Pharm. Co., Ltd	Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
JP7148605B2 (ja) *	2017-10-12	2022-10-05	ノヴォノルディスクアー／エス	医学療法におけるセマグルチド
CN107881187A (zh) *	2017-11-20	2018-04-06	珠海联邦制药股份有限公司	将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
EP3728304B1 (en) *	2017-12-21	2025-02-12	Bachem Holding AG	Solid phase synthesis of acylated peptides
PL3746111T3 (pl)	2018-02-02	2024-01-15	Novo Nordisk A/S	Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
WO2019157099A1 (en)	2018-02-06	2019-08-15	Aegis Therapeutics, Llc	Intranasal epinephrine formulations and methods for the treatment of disease
CN110294800B (zh) *	2018-03-22	2022-03-04	齐鲁制药有限公司	一种索玛鲁肽的制备方法
EP3774902A1 (en)	2018-04-02	2021-02-17	Bristol-Myers Squibb Company	Anti-trem-1 antibodies and uses thereof
RS63523B1 (sr)	2018-04-05	2022-09-30	Sun Pharmaceutical Ind Ltd	Novi glp-1 analozi
EP3773475A1 (en)	2018-04-06	2021-02-17	Cyprumed GmbH	Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (zh)	2018-04-19	2019-10-24	杭州先为达生物科技有限公司	酰化的glp-1衍生物
CN110386974B (zh) *	2018-04-19	2022-12-09	杭州先为达生物科技有限公司	Glp-1衍生物及其治疗用途
KR102379958B1 (ko)	2018-05-04	2022-04-01	노보 노르디스크 에이/에스	Gip 유도체 및 이의 용도
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
HRP20230929T1 (hr)	2018-10-26	2023-11-24	Novo Nordisk A/S	Stabilni pripravci semaglutida i njihova upotreba
CN109180801B (zh) *	2018-11-01	2021-08-13	汉肽生物医药集团有限公司	一种合成索玛鲁肽的方法
CN121449721A (zh)	2018-12-03	2026-02-03	安泰博医药	经修饰的gip肽类似物
EP3897570A1 (en)	2018-12-19	2021-10-27	KRKA, d.d., Novo mesto	Pharmaceutical composition comprising glp-1 analogue
CN113194929B (zh)	2018-12-21	2022-12-09	诺和诺德股份有限公司	Glp-1肽的喷雾干燥工艺
US20220072493A1 (en)	2019-01-24	2022-03-10	Novo Nordisk A/S	Roller compactor and method of dry granulation using a roller compactor
JP7695885B2 (ja)	2019-02-12	2025-06-19	アンブルックス，インコーポレイテッド	抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
WO2020169658A2 (en)	2019-02-20	2020-08-27	Novo Nordisk A/S	Aminoacyl-trna synthetases and uses hereof
EP3930757A1 (en)	2019-03-01	2022-01-05	President And Fellows Of Harvard College	Methods and compositions for protein delivery
WO2020190757A1 (en)	2019-03-15	2020-09-24	Novetide Ltd.	Improved processes for the preparation of semaglutide
MA55278A (fr) *	2019-03-15	2022-01-19	Novo Nordisk As	Procédé de séchage à pulvérisation d'un peptide glp-1
CN111748019A (zh) *	2019-03-29	2020-10-09	深圳翰宇药业股份有限公司	一种多肽衍生化合物的合成方法
CN120518763A (zh)	2019-04-01	2025-08-22	诺和诺德股份有限公司	针对利拉鲁肽的抗体及其用途
MX2021012277A (es) *	2019-04-11	2021-11-12	Jiangsu Hansoh Pharmaceutical Group Co Ltd	Agonista multireceptor y uso medico del mismo.
CN111909256A (zh) *	2019-05-10	2020-11-10	宁波鲲鹏生物科技有限公司	多肽衍生物及其制备方法
EP3972630A1 (en) *	2019-05-21	2022-03-30	MedImmune Limited	Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
CN114340655A (zh)	2019-09-02	2022-04-12	诺和诺德股份有限公司	生产包含glp-1肽的片剂的方法
BR112022004697A2 (pt) *	2019-09-16	2022-06-14	Biomarin Pharm Inc	Variantes de cnp e conjugados das mesmas
CN110590934B (zh) *	2019-09-25	2020-12-08	北京乐普医药科技有限公司	一种glp-1化合物
CA3154744A1 (en)	2019-11-06	2021-05-14	Sarah FRIEDRICH	Glp-1 receptor agonists in dementia
EP3819308A1 (en)	2019-11-07	2021-05-12	Fresenius Kabi iPSUM S.r.l.	Process for the manufacture of derivatized amino acids
CN114641276A (zh)	2019-11-07	2022-06-17	诺和诺德股份有限公司	包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
WO2021105393A1 (en)	2019-11-29	2021-06-03	Novo Nordisk A/S	Processes for obtaining stable glp-1 compositions
AU2020397917A1 (en)	2019-12-04	2022-06-23	The Scripps Research Institute	GLP2 receptor agonists and methods of use
WO2021123228A1 (en)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
CN119529057A (zh)	2019-12-30	2025-02-28	甘李药业股份有限公司	长效glp-1化合物
CN115260313B (zh)	2019-12-31	2023-07-18	北京质肽生物医药科技有限公司	Glp-1和gdf15的融合蛋白以及其缀合物
CN115322794B (zh)	2020-01-11	2025-09-19	北京质肽生物医药科技有限公司	Glp-1和fgf21的融合蛋白的缀合物
CN119841865A (zh)	2020-02-07	2025-04-18	加舒布鲁姆生物公司	杂环glp-1激动剂
EP4104820A4 (en)	2020-02-14	2024-04-17	G2GBIO, Inc.	Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
PE20230819A1 (es)	2020-02-18	2023-05-19	Novo Nordisk As	Composiciones y usos de glp-1
CN111253475B (zh)	2020-02-18	2021-03-09	江苏诺泰澳赛诺生物制药股份有限公司	Glp-1激动多肽化合物及其盐与合成方法及用途
US12552742B2 (en)	2020-04-10	2026-02-17	Fresenius Kabi Oncology Ltd	Process for the preparation of Semaglutide side chain
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
EP4142695B1 (en)	2020-04-29	2025-11-05	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist and histidine
FI4143183T3 (fi)	2020-04-29	2026-01-07	Gasherbrum Bio Inc	Heterosyklisiä glp-1-agonisteja
AR122579A1 (es) *	2020-06-12	2022-09-21	Lilly Co Eli	Proceso para preparar un agonista dual glp-1 / glucagón
BR112023000229A2 (pt)	2020-07-22	2023-01-31	Novo Nordisk As	Composto, composição farmacêutica, e, peptídeo
PE20231181A1 (es)	2020-08-06	2023-08-11	Gasherbrum Bio Inc	Agonistas del glp-1 heterociclicos
EP4199968A1 (en)	2020-08-20	2023-06-28	Ambrx, Inc.	Antibody-tlr agonist conjugates, methods and uses thereof
WO2022049310A1 (en)	2020-09-07	2022-03-10	Cyprumed Gmbh	Improved pharmaceutical formulations of glp-1 receptor agonists
CN114729060B (zh) *	2020-09-30	2022-11-25	北京质肽生物医药科技有限公司	多肽缀合物和使用方法
MY206918A (en)	2020-11-06	2025-01-17	Novo Nordisk As	Glp-1 prodrugs and uses hereof
TWI850611B (zh)	2020-12-18	2024-08-01	丹麥商諾佛儂迪克股份有限公司	Glp-1及澱粉素受體之共促效劑
CN115124602B (zh)	2021-03-25	2024-01-26	博瑞生物医药（苏州）股份有限公司	Gip和glp-1的双受体激动剂、药物组合物及用途
US20250161471A1 (en)	2021-04-03	2025-05-22	Feng Tian	Anti-her2 antibody-drug conjugates and uses thereof
TW202304500A (zh)	2021-04-21	2023-02-01	瑞士商諾華公司	升糖素樣肽化合物
MX2023014771A (es)	2021-06-09	2024-03-19	Scripps Research Inst	Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
KR20240021212A (ko)	2021-06-10	2024-02-16	안타그 테라퓨틱스 에이피에스	비만 및 비만-관련 장애의 치료
CN117580579A (zh)	2021-06-10	2024-02-20	纽瑞莱斯有限公司	用于治疗儿科患者的癫痫发作病症的方法和组合物
WO2022270956A1 (ko)	2021-06-23	2022-12-29	주식회사 펩트론	세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물
EP4360645A4 (en) *	2021-06-25	2025-09-10	Gan & Lee Pharmaceuticals Co Ltd	PHARMACEUTICAL COMPOSITION CONTAINING A GLP-1 COMPOUND
CN117580583A (zh)	2021-06-25	2024-02-20	甘李药业股份有限公司	Pcsk9抑制剂和glp-1受体激动剂的药物组合
WO2023285334A1 (en)	2021-07-12	2023-01-19	Novo Nordisk A/S	Novel fatty acid modified urocortin 2 derivatives and the uses thereof
CA3224743A1 (en)	2021-07-14	2023-01-19	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion polypeptides for metabolic disorders
AU2022312702A1 (en)	2021-07-15	2024-01-18	Novo Nordisk A/S	Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN116410297A (zh) *	2021-07-19	2023-07-11	内蒙古博睿精创科技有限公司	长效glp-1多肽类似物及其制备方法和应用
WO2023012263A1 (en)	2021-08-04	2023-02-09	Novo Nordisk A/S	Solid oral peptide formulations
WO2023038039A1 (ja)	2021-09-08	2023-03-16	塩野義製薬株式会社	抗肥満作用の関与する疾患の予防及び治療用医薬
EP4429704A4 (en)	2021-11-10	2025-11-05	I2O Therapeutics Inc	IONIC LIQUID COMPOSITIONS
WO2023110833A1 (en)	2021-12-13	2023-06-22	Novo Nordisk A/S	Pharmaceutical formulations comprising a cyclodextrin
CA3236278A1 (en)	2021-12-13	2023-06-22	Kennett Sprogoe	Effective doses of cnp conjugates
CN119137124A (zh)	2022-03-09	2024-12-13	加舒布鲁姆生物公司	杂环glp-1激动剂
WO2023179542A1 (en)	2022-03-21	2023-09-28	Gasherbrum Bio , Inc.	5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4323413A4 (en)	2022-03-30	2025-10-15	Beijing Ql Biopharmaceutical Co Ltd	LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
WO2023187067A1 (en)	2022-03-30	2023-10-05	Novo Nordisk A/S	Formulation method
WO2023198140A1 (en)	2022-04-14	2023-10-19	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
JP2025517672A (ja)	2022-05-10	2025-06-10	ノヴォノルディスクアー／エス	プロドラッグおよびその使用
IL316466A (en)	2022-05-23	2024-12-01	Ascendis Pharma Growth Disorders As	Liquid pharmaceutical formulations of cnp compounds
JP2025521774A (ja)	2022-07-05	2025-07-10	ジー２ジーバイオインコーポレイテッド	セマグルチドまたはその薬学的に許容可能な塩を含む徐放性微粒球製剤およびその製造方法
WO2024068848A1 (en)	2022-09-28	2024-04-04	Zealand Pharma A/S	Methods for treating obesity
WO2024079043A1 (en)	2022-10-10	2024-04-18	Bachem Holding Ag	Method of manufacturing a peptide with a lysine derivative
WO2024104922A1 (en)	2022-11-14	2024-05-23	Ascendis Pharma Growth Disorders A/S	Method of improving skeletal muscle function
TW202421645A (zh)	2022-11-25	2024-06-01	丹麥商諾佛儂迪克股份有限公司	如ｇｌｐ—１之肽治療劑的口服投與
WO2024128882A1 (ko)	2022-12-16	2024-06-20	주식회사 펩트론	Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도
CN116159027A (zh) *	2022-12-29	2023-05-26	江苏诺泰澳赛诺生物制药股份有限公司	一种司美格鲁肽冻干药物组合物及其制备方法
JP2026502943A (ja)	2022-12-30	2026-01-27	アルギファルマエーエス	経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
CN120731085A (zh) *	2023-03-02	2025-09-30	甘李药业股份有限公司	一种glp-1化合物的医药用途
WO2024184352A1 (en)	2023-03-06	2024-09-12	Ascendis Pharma A/S	Drug compounds comprising albumin-binding moieties
AU2024232125A1 (en)	2023-03-06	2025-08-28	Ascendis Pharma A/S	Compounds of drugs with an albumin binding moiety
WO2024184354A1 (en)	2023-03-06	2024-09-12	Ascendis Pharma A/S	Multi-albumin binding compounds
AU2024240722A1 (en)	2023-03-20	2025-09-18	Ascendis Pharma Growth Disorders A/S	Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
PE20252745A1 (es)	2023-03-30	2025-12-05	Novo Nordisk As	Compuestos de fusion y usos de estos
WO2024234320A1 (zh) *	2023-05-17	2024-11-21	南京知和医药科技有限公司	一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
EP4724471A1 (en)	2023-06-09	2026-04-15	Sun Pharmaceutical Industries Limited	Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
EP4727524A1 (en)	2023-06-15	2026-04-22	Novo Nordisk A/S	Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin
WO2025069009A1 (en)	2023-09-29	2025-04-03	Graviton Bioscience Bv	Rock2 inhibitors in the treatment of obesity
WO2025077751A1 (zh) *	2023-10-09	2025-04-17	甘李药业股份有限公司	Glp-1肽组合物及其用途
WO2025078040A1 (en)	2023-10-09	2025-04-17	Bachem Holding Ag	Lysine salt and method of manufacturing a lysine derivative
TW202521100A (zh)	2023-11-17	2025-06-01	美商雅沛尼美德公司（德拉瓦州公司）	使用ｇｌｐ－１受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
JP7755031B2 (ja)	2023-11-30	2025-10-15	ノヴォノルディスクアー／エス	Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (en)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitors of expression and/or function
WO2025169190A2 (en)	2024-02-06	2025-08-14	Opko Biologics Ltd.	Modified oxyntomodulin and methods of use thereof
EP4603080A1 (en)	2024-02-16	2025-08-20	Adocia	Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721761A1 (en)	2024-10-07	2026-04-08	Adocia	Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en)	2024-02-16	2025-08-21	Adocia	Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684801A1 (en)	2024-07-23	2026-01-28	Adocia	Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172606A1 (en)	2024-02-16	2025-08-21	Adocia	Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721760A1 (en)	2024-10-07	2026-04-08	Adocia	Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684802A1 (en)	2024-07-23	2026-01-28	Adocia	Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en)	2024-02-16	2025-08-20	Adocia	Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
GB202403746D0 (en)	2024-03-15	2024-05-01	New Roger Randal Charles	Formulations demonstrating an oral depot effect
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025231285A1 (en) *	2024-05-02	2025-11-06	Kallyope, Inc.	Peptide analogs and methods of using the same
WO2025248124A1 (en)	2024-05-31	2025-12-04	Zealand Pharma A/S	Dapiglutide for use in treating a sub-group of subjects
WO2026008836A1 (en)	2024-07-05	2026-01-08	Novo Nordisk A/S	Glp-1 derivatives and uses thereof
WO2026013136A1 (en)	2024-07-10	2026-01-15	Ascendis Pharma A/S	Albumin-binding compounds
WO2026013135A1 (en)	2024-07-10	2026-01-15	Ascendis Pharma A/S	Albumin-binding reagents
WO2026013138A1 (en)	2024-07-10	2026-01-15	Ascendis Pharma A/S	Compounds with improved albumin-binding
WO2026073030A1 (en)	2024-09-27	2026-04-02	Carmot Therapeutics Inc.	Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists
DK182293B1 (en)	2025-01-16	2026-02-25	Novo Nordisk As	Semaglutide for use in medical therapy including weight management

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04504246A (ja)	1989-03-20	1992-07-30	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン刺激ホルモン
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5336782A (en)	1991-04-24	1994-08-09	Kuraray Co., Ltd.	Long chain carboxylic acid imide ester
US5869602A (en)	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
EP0929576A1 (en)	1996-08-30	1999-07-21	Novo Nordisk A/S	Glp-2 derivatives
IL128332A0 (en) *	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
AU2712899A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU2610599A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
EP1062240B1 (en) *	1998-02-27	2010-04-28	Novo Nordisk A/S	N-terminally modified glp-1 derivatives
EP1061946B1 (en)	1998-02-27	2004-04-28	Novo Nordisk A/S	Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2003522099A (ja)	1998-02-27	2003-07-22	ノボノルディスクアクティーゼルスカブ	遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
DE69922043T2 (de)	1998-12-07	2005-11-24	Société de Conseils de Recherches et d'Applications Scientifiques S.A.S.	Glp-1 analoge
CA2363712C (en)	1999-05-17	2011-05-10	Conjuchem Inc.	Long lasting insulinotropic peptides
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US20040001827A1 (en)	2002-06-28	2004-01-01	Dennis Mark S.	Serum albumin binding peptides for tumor targeting
WO2001051071A2 (en)	2000-01-11	2001-07-19	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
BR0116024A (pt)	2000-12-07	2005-12-13	Lilly Co Eli	Proteìna de fusão heteróloga e uso da mesma
FR2819810B1 (fr)	2001-01-23	2004-05-28	Pf Medicament	Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en)	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
AU2002316811A1 (en)	2001-06-28	2003-03-03	Novo Nordisk A/S	Stable formulation of modified glp-1
JP2004537580A (ja)	2001-08-10	2004-12-16	エピックスメディカル，インコーポレイテッド	延長された循環半減期を有するポリペプチド結合体
AR036711A1 (es)	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
MXPA04006679A (es)	2002-01-08	2004-11-10	Lilly Co Eli	Analogos extendidos de peptido-1 de tipo glucagon.
US20050100963A1 (en)	2002-03-01	2005-05-12	Dyax Corporation	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
IL164266A0 (en)	2002-04-10	2005-12-18	Lilly Co Eli	Treatment of gastroparesis
JP2007524579A (ja)	2003-02-19	2007-08-30	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	Ｇｌｐ−１の類似体
EP1605897B1 (en)	2003-03-19	2012-07-25	Eli Lilly And Company	Polyethelene glycol link glp-1 compounds
BRPI0409976A (pt)	2003-05-09	2006-05-09	Novo Nordisk As	composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
EP1654004A2 (en) *	2003-08-08	2006-05-10	Novo Nordisk A/S	Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
JP2007537981A (ja)	2003-09-19	2007-12-27	ノボ　ノルディスク　アクティーゼルスカブ	新規の血漿タンパク質親和性タグ
RU2401276C2 (ru)	2003-09-19	2010-10-10	Ново Нордиск А/С	Производные глюкагон-подобного пептида-1 (glp-1)
KR101241862B1 (ko) *	2003-09-19	2013-03-13	노보 노르디스크 에이/에스	신규 ｇｌｐ-1 유도체
MXPA06006745A (es)	2003-12-18	2006-08-18	Novo Nordisk As	Compuestos glp-1 novedosos.
JP2007537142A (ja)	2003-12-18	2007-12-20	ノボ　ノルディスク　アクティーゼルスカブ	アルブミン様物質に結合した新規のｇｌｐ−１類似物
MXPA06015049A (es)	2004-07-08	2007-02-08	Novo Nordisk As	Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
US7893017B2 (en)	2004-10-07	2011-02-22	Novo Nordisk A/S	Protracted GLP-1 compounds
RU2413530C9 (ru)	2004-11-12	2021-05-18	Ново Нордиск А/С	Стабильные препараты инсулинотропных пептидов
JP5755398B2 (ja)	2005-03-18	2015-07-29	ノヴォノルディスクアー／エス	伸長されたｇｌｐ−１化合物
TWI372629B (en)	2005-03-18	2012-09-21	Novo Nordisk As	Acylated glp-1 compounds
WO2006097536A2 (en)	2005-03-18	2006-09-21	Novo Nordisk A/S	Dimeric peptide agonists of the glp-1 receptor

2006
- 2006-03-17 TW TW098124221A patent/TWI372629B/zh active
- 2006-03-17 TW TW095109086A patent/TWI362392B/zh active
- 2006-03-20 PL PL06725149T patent/PL1863839T3/pl unknown
- 2006-03-20 AU AU2006224536A patent/AU2006224536B9/en active Active
- 2006-03-20 DK DK10169546.8T patent/DK2322546T3/en active
- 2006-03-20 CN CN201410513914.8A patent/CN104402989A/zh not_active Withdrawn
- 2006-03-20 PL PL10169546T patent/PL2322546T3/pl unknown
- 2006-03-20 DE DE602006015928T patent/DE602006015928D1/de not_active Expired - Lifetime
- 2006-03-20 KR KR1020077017241A patent/KR101205272B1/ko not_active Expired - Lifetime
- 2006-03-20 WO PCT/EP2006/060855 patent/WO2006097537A2/en not_active Ceased
- 2006-03-20 PT PT101695468T patent/PT2322546E/pt unknown
- 2006-03-20 MX MX2007011220A patent/MX2007011220A/es active IP Right Grant
- 2006-03-20 CN CN200680006674.6A patent/CN101133082B/zh not_active Expired - Lifetime
- 2006-03-20 ES ES06725149T patent/ES2350051T3/es not_active Expired - Lifetime
- 2006-03-20 HU HUE10169546A patent/HUE028194T2/en unknown
- 2006-03-20 DK DK06725149.6T patent/DK1863839T3/da active
- 2006-03-20 RU RU2007134156A patent/RU2434019C3/ru active Protection Beyond IP Right Term
- 2006-03-20 EP EP06725149A patent/EP1863839B1/en not_active Expired - Lifetime
- 2006-03-20 AT AT06725149T patent/ATE476446T1/de active
- 2006-03-20 BR BR122019002626A patent/BR122019002626A2/pt not_active Application Discontinuation
- 2006-03-20 CN CN201310534370.9A patent/CN104017062A/zh not_active Withdrawn
- 2006-03-20 JP JP2008501334A patent/JP5209463B2/ja not_active Expired - Lifetime
- 2006-03-20 PT PT06725149T patent/PT1863839E/pt unknown
- 2006-03-20 EP EP10169546.8A patent/EP2322546B1/en not_active Expired - Lifetime
- 2006-03-20 ES ES10169546.8T patent/ES2557313T3/es not_active Expired - Lifetime
- 2006-03-20 US US11/908,834 patent/US8129343B2/en active Active
- 2006-03-20 CA CA2601784A patent/CA2601784C/en not_active Expired - Fee Related
- 2006-03-20 BR BRPI0607762A patent/BRPI0607762B8/pt active IP Right Grant
2007
- 2007-06-19 IL IL184051A patent/IL184051A/en active Protection Beyond IP Right Term
- 2007-08-28 ZA ZA200707261A patent/ZA200707261B/en unknown
- 2007-10-18 NO NO20075342A patent/NO337946B1/no active Protection Beyond IP Right Term
2010
- 2010-01-19 JP JP2010009025A patent/JP4585037B2/ja not_active Expired - Lifetime
2012
- 2012-03-05 US US13/412,283 patent/US8536122B2/en not_active Expired - Lifetime
- 2012-11-02 JP JP2012242654A patent/JP2013063984A/ja not_active Withdrawn
2018
- 2018-04-19 BE BE2018C016C patent/BE2018C016I2/fr unknown
- 2018-04-24 NL NL300936C patent/NL300936I2/nl unknown
- 2018-04-24 HU HUS1800019C patent/HUS1800019I1/hu unknown
- 2018-04-26 FR FR18C1017C patent/FR18C1017I2/fr active Active
- 2018-07-05 NO NO2018023C patent/NO2018023I1/no unknown

Also Published As

Publication number	Publication date
JP2013063984A (ja)	2013-04-11
RU2434019C2 (ru)	2011-11-20
US8536122B2 (en)	2013-09-17
FR18C1017I1 (fr)	2018-06-15
JP2008533105A (ja)	2008-08-21
CN101133082B (zh)	2016-01-13
CN101133082A (zh)	2008-02-27
NO20075342L (no)	2007-12-18
PT1863839E (pt)	2010-11-10
HUE028194T2 (en)	2016-12-28
BR122019002626A2 (2)	2019-04-02
DE602006015928D1 (de)	2010-09-16
DK2322546T3 (en)	2015-12-14
BRPI0607762B8 (pt)	2021-05-25
ZA200707261B (en)	2008-05-28
TWI372629B (en)	2012-09-21
RU2434019C3 (ru)	2020-07-20
TWI362392B (en)	2012-04-21
EP2322546A1 (en)	2011-05-18
WO2006097537A3 (en)	2007-01-25
TW200942255A (en)	2009-10-16
ES2557313T3 (es)	2016-01-25
PT2322546E (pt)	2016-01-22
US8129343B2 (en)	2012-03-06
PL1863839T3 (pl)	2011-01-31
MX2007011220A (es)	2007-10-17
US20090156478A1 (en)	2009-06-18
BE2018C016I2 (2)	2025-09-05
JP2010116407A (ja)	2010-05-27
NO2018023I1 (2)	2018-07-05
AU2006224536A1 (en)	2006-09-21
AU2006224536B9 (en)	2012-05-10
RU2007134156A (ru)	2009-04-27
TW200700433A (en)	2007-01-01
BRPI0607762B1 (pt)	2019-05-07
DK1863839T3 (da)	2010-11-22
CA2601784A1 (en)	2006-09-21
CN104402989A (zh)	2015-03-11
ES2350051T3 (es)	2011-01-17
KR20070120089A (ko)	2007-12-21
US20120295847A1 (en)	2012-11-22
NL300936I2 (nl)	2018-08-07
FR18C1017I2 (fr)	2019-05-17
NO337946B1 (no)	2016-07-18
BRPI0607762A2 (pt)	2010-03-23
CN104017062A (zh)	2014-09-03
WO2006097537A2 (en)	2006-09-21
IL184051A0 (en)	2007-10-31
PL2322546T3 (pl)	2016-03-31
HUS1800019I1 (hu)	2018-06-28
EP2322546B1 (en)	2015-09-30
IL184051A (en)	2015-08-31
EP1863839A2 (en)	2007-12-12
AU2006224536B2 (en)	2012-04-05
EP1863839B1 (en)	2010-08-04
JP4585037B2 (ja)	2010-11-24
CA2601784C (en)	2013-12-24
ATE476446T1 (de)	2010-08-15
KR101205272B1 (ko)	2013-01-11

Legal Events

Date	Code	Title	Description
2008-09-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080916
2008-09-17	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080916
2011-04-06	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110405
2011-06-24	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110623
2011-07-01	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110630
2011-10-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111005
2012-05-30	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120529
2012-07-04	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120703
2012-11-03	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121102
2012-11-14	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121113
2013-01-18	TRDD	Decision of grant or rejection written
2013-01-23	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130122
2013-02-28	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130221
2013-03-01	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20160301 Year of fee payment: 3
2013-03-01	R150	Certificate of patent or registration of utility model	Ref document number: 5209463 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150
2016-03-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-03-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-03-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-01-16	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2019-03-12	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-03-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-03-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-10-06	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2022-03-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-03-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-01-24	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2024-03-01	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-03-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2026-01-21	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2026-01-29	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153

Publication	Publication Date	Title
JP5209463B2 (ja)	2013-06-12	アシル化ｇｌｐ−１化合物
JP5755398B2 (ja)	2015-07-29	伸長されたｇｌｐ−１化合物
JP5606314B2 (ja)	2014-10-15	Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途
US9012398B2 (en)	2015-04-21	Acylated exendin-4 compounds
JP5476304B2 (ja)	2014-04-23	グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
WO2009030774A1 (en)	2009-03-12	Truncated glp-1 derivatives and their therapeutical use